The price trend for Vanda Pharmaceuticals (VNDA) has been bearish lately and the stock has lost 5.8% over the past week.

Less than two weeks ago, Vanda scored an FDA approval for motion sickness pill, Nereus. The decision came 15 months after the ...

The Beltway-based biopharma disputed the FDA’s conclusions regarding the data provided in its supplemental application for ...

The average one-year price target for Vanda Pharmaceuticals (NasdaqGM:VNDA) has been revised to $13.90 / share. This is an ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares are trading higher Wednesday after the company announced it received FDA ...

Exante Data is a data analytics and global macro strategy provider. FPE portfolio company Vanda has acquired Exante Data, a ...

Vanda Pharmaceuticals (VNDA) stock hit a two-year high on news it filed a FDA application for its psoriasis drug ...

Analysts raise price targets for Vanda Pharmaceuticals after FDA approved a motion sickness drug, citing growth potential.

Jefferies analysts envision a steady launch curve that could ultimately drive meaningful sales from people who are ...

Vanda Pharmaceuticals (VNDA) stock rises as the FDA approves its motion sickness therapy Nereus, developed in partnership ...

US drugmaker Vanda Pharmaceuticals yesterday announced that it has received a decision letter from the US Food and Drug ...

The approval marks the first new pharmacologic treatment in motion sickness in over four decades. The US Food and Drug ...